Symvivo Corporation
Burnaby
About Symvivo Corporation
Symvivo Corporation is a platform that delivers plasmid DNA, both orally and through IV administration, that enables a patient’s own cells to produce biologics. They make therapeutic developments in the fields of oral vaccines, cancer, immunology, and biologics. Symvivo Corporation is creating the next generation of vaccines by offering orally delivered, room-temperature stable medicines that can generate both systemic and mucosal immunity, as well as scalable and cost-effective manufacturing procedures.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $650.0K
- Last round: Grant (May 2022)
- Website: symvivo.comabout
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/symvivo-corporation-33605 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.